Orchestra BioMed Holdings, Inc.
OBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2,638 | $2,760 | $3,533 | -$782 |
| % Growth | -4.4% | -21.9% | 551.8% | – |
| Cost of Goods Sold | $204 | $186 | $322 | $199 |
| Gross Profit | $2,434 | $2,574 | $3,211 | -$981 |
| % Margin | 92.3% | 93.3% | 90.9% | 125.4% |
| R&D Expenses | $42,804 | $33,822 | $21,945 | $12,890 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $23,931 | $20,258 | $13,923 | $7,928 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $66,735 | $54,080 | $35,868 | $20,818 |
| Operating Income | -$64,301 | -$51,506 | -$32,657 | -$21,799 |
| % Margin | -2,437.5% | -1,866.2% | -924.3% | 2,787.6% |
| Other Income/Exp. Net | $3,277 | $2,386 | -$951 | -$1,215 |
| Pre-Tax Income | -$61,024 | -$49,120 | -$33,608 | -$23,014 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$61,024 | -$49,120 | -$33,608 | -$23,014 |
| % Margin | -2,313.3% | -1,779.7% | -951.3% | 2,943% |
| EPS | -1.66 | -1.48 | -1.32 | -0.019 |
| % Growth | -12.2% | -12.1% | -7,035.1% | – |
| EPS Diluted | -1.66 | -1.48 | -1.32 | -0.019 |
| Weighted Avg Shares Out | 36,821 | 33,225 | 25,472 | 20,450 |
| Weighted Avg Shares Out Dil | 36,821 | 33,225 | 25,472 | 20,450 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,356 | $3,849 | $50 | $0 |
| Interest Expense | $0 | $0 | $0 | $927 |
| Depreciation & Amortization | $308 | $287 | $222 | $181 |
| EBITDA | -$63,993 | -$51,219 | -$32,435 | -$21,618 |
| % Margin | -2,425.8% | -1,855.8% | -918.1% | 2,764.5% |